---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-029279"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:05:55.120685+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Diffusion settles proxy contest with LifeSci; may appoint director if no deal by July 2023

## Summary
- LifeSci Special Opportunities withdraws its director nominees and will vote for Diffusion's slate at Dec 30 annual meeting.
- If no strategic transaction (e.g., sale, merger) completed by July 1, 2023, Diffusion must appoint a LifeSci-designated director.
- LifeSci, owning ~4.8% of DFFN shares, agrees to standstill and voting commitments through at least Dec 31, 2024.
- Diffusion to reimburse LifeSci up to $50,000 for expenses related to nomination and negotiation.

## SEC filing metadata
- accession: 0001437749-22-029279
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/0001437749-22-029279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/dffn20221215_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-029279
- JSON: https://secwatch.observer/filing/0001437749-22-029279.json
- Plain text: https://secwatch.observer/filing/0001437749-22-029279.txt

## Key facts
- Material Agreements
  CervoMed Inc. entered into Agreement with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (effective 2022-12-15).
  - Action: entry
  - Agreement: settlement
  - Counterparty: LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates
  - Effective: 2022-12-15
  source text: On December 15, 2022, Diffusion Pharmaceuticals Inc. (the “ Company ”) entered into a binding settlement agreement (the “ Agreement ”) with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (collectively, “ LifeSci Special Opportunities ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/0001437749-22-029279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.